請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65510
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳燕惠(Yen-Hui Chen) | |
dc.contributor.author | Wei-Ting Wang | en |
dc.contributor.author | 王韋婷 | zh_TW |
dc.date.accessioned | 2021-06-16T23:47:26Z | - |
dc.date.available | 2017-09-19 | |
dc.date.copyright | 2012-09-19 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-07-23 | |
dc.identifier.citation | 1. Prostate cancer. American cancer society 2012.
2. Nelson, W. G.; De Marzo, A. M.; Isaacs, W. B., Prostate Cancer. New England Journal of Medicine 2003, 349 , 366-381. 3. Ma, R. W. L.; Chapman, K., A systematic review of the effect of diet in prostate cancer prevention and treatment. Journal of Human Nutrition and Dietetics 2009, 22 , 187-199. 4. Cancer Facts & Figures 2012. Atlanta, Ga: American Cancer Society 2012. 5. 中華民國99年行政院衛生署死因統計結果. 6. Wolf, A. M. D.; Wender, R. C.; Etzioni, R. B.; Thompson, I. M.; D'Amico, A. V.; Volk, R. J.; Brooks, D. D.; Dash, C.; Guessous, I.; Andrews, K.; DeSantis, C.; Smith, R. A., American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010. CA: A Cancer Journal for Clinicians 2010, 60 , 70-98. 7. Sam, C. S., Treatment Options for Hormone-Refractory Prostate Cancer. Reviews in Urology 2007, 9, S13-S18. 8. Stavridi, F.; Karapanagiotou, E. M.; Syrigos, K. N., Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treatment Reviews 2010, 36 , 122-130. 9. Paller, C. J.; Antonarakis, E. S., Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug design, development and therapy 2011, 5, 117-124. 10. Shelley M, H. C., Coles B, Staffurth J, Wilt TJ, Mason MD., Chemotherapy for hormone-refractory prostate cancer. Cochrane Database of Systematic Reviews 2006, 4, 1-68. 11. Fred, S., Therapeutic Approach to Hormone-refractory Prostate Cancer. European Urology Review 2007, 1, 23-25. 12. Skjoth, I. H. E.; Issinger, O. G., Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis. International Journal of Oncology 2006, 28, 217-229. 13. Blaya, B.; Nicolau-Galmes, F.; Jangi, S. M.; Ortega-Martinez, I.; Alonso-Tejerina, E.; Burgos-Bretones, J.; Perez-Yarza, G.; Asumendi, A.; Boyano, M. D., Histamine and Histamine Receptor Antagonists in Cancer Biology. Inflammation & Allergy - Drug Targets 2010, 9, 146-157. 14. Jones, B. L.; Kearns, G. L., Histamine: New Thoughts About a Familiar Mediator. Clinical Pharmacology&Therapeutics 2011, 89, 189-197. 15. Cianchi, F.; Cristina Vinci, M.; Masini, E., Histamine in cancer: The dual faces of the coin. Cancer Biology & Therapy 2008, 7, 36-37. 16. Graff, L.; Frungieri, M.; Zanner, R.; Pohlinger, A.; Prinz, C.; Gratzl, M., Expression of Histidine Decarboxylase and Synthesis of Histamine by Human Small Cell Lung Carcinoma. The American Journal of Pathology 2002, 160, 1561-1565. 17. Garcia-Caballero, M.; Neugebauer, E.; Rodriguez, F.; De Castro, I. N.; Vara-Thorbeck, C., Histamine synthesis and content in benign and malignant breast tumours. Its effects on other host tissues. Surgical Oncology 1994, 3, 167-173. 18. Garcia-Caballero, M.; Neugebauer, E.; Campos, R.; Nunez de Castro, I.; Vara-Thorbeck, C., Increased histidine decarboxylase (HDC) activity in human colorectal cancer: Results of a study on ten patients. Inflammation Research 1988, 23, 357-360. 19. Chanda, R.; Ganguly, A. K., Diamine-oxidase activity and tissue di- and poly-amine contents of human ovarian, cervical and endometrial carcinoma. Cancer Letters 1995, 89, 23-28. 20. Vanina, A. M. E., S. Rivera, Histamine receptors and cancer pharmacology. British Journal of Pharmacology 2010, 161, 755-767. 21. Criado PR, C. R., Maruta CW, Machado Filho C., Histamine, histamine receptors and antihistamines: new concepts. The Branzilian Annals of Dermatology 2010, 85, 195-210. 22. Parsons, M. E.; Ganellin, C. R., Histamine and its receptors. British Journal of Pharmacology 2006, 147, S127-S135. 23. Simons, F. E. R.; Simons, K. J., Histamine and H1-antihistamines: Celebrating a century of progress. Journal of Allergy and Clinical Immunology 2011, 128, 1139-1150.e4. 24. Church, M. K.; Maurer, M.; Simons, F. E. R.; Bindslev-Jensen, C.; Van Cauwenberge, P.; Bousquet, J.; Holgate, S. T.; Zuberbier, T., Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy 2010, 65, 459-466. 25. Ellis, A. K.; Day, J. H., Second- and third-generation antihistamines in the treatment of urticaria. Dermatologic Therapy 2000, 13, 327-336. 26. Bauman, J. L., The role of pharmacokinetics, drug interactions and pharmacogenetics in the acquired long QT syndrome. European Heart Journal Supplements 2001, 3, K93-K100. 27. Simons, F. E. R., Advances in H1-Antihistamines. New England Journal of Medicine 2004, 351, 2203-2217. 28. Jangi, S. M.; Asumendi, A.; Arlucea, J.; Nieto, N.; Perez-Yarza, G.; Morales, M. C.; de la Fuente-Pinedo, M.; Boyano, M. D., Apoptosis of Human T-Cell Acute Lymphoblastic Leukemia Cells by Diphenhydramine, an H1 Histamine Receptor Antagonist. Oncology Research Incorporating Anti-Cancer Drug Design 2004, 14 , 363-372. 29. Hadzijusufovic, E.; Peter, B.; Gleixner, K. V.; Schuch, K.; Pickl, W. F.; Thaiwong, T.; Yuzbasiyan-Gurkan, V.; Mirkina, I.; Willmann, M.; Valent, P., H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Experimental Hematology 2010, 38, 896-907. 30. Liu, J.-D.; Wang, Y.-J.; Chen, C.-H.; Yu, C.-F.; Chen, L.-C.; Lin, J.-K.; Liang, Y.-C.; Lin, S.-Y.; Ho, Y.-S., Molecular mechanisms of G0/G1 cell-cycle arrest and apoptosis induced by terfenadine in human cancer cells. Molecular Carcinogenesis 2003, 37, 39-50. 31. Wang, Y.-J. Y., Cheng-Fei; Chen, Li-Ching; Chen, Chien-Ho; Lin, Jen-Kun; Liang, Yu-Chih; Lin, Chien-Huang; Lin, Shyr-Yi; Chen, Chin-Fa; Ho, Yuan-Soon, Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity. Journal of Cellular Biochemistry 2002, 87, 147-159. 32. Falus, A.; Hegyesi, H.; Lazar-Molnar, E.; Pos, Z.; Laszlo, V.; Darvas, Z., Paracrine and autocrine interactions in melanoma: histamine is a relevant player in local regulation. Trends in Immunology 2001, 22, 648-652. 33. Jangi, S.-M.; Díaz-Pérez, J. L.; Ochoa-Lizarralde, B.; Martín-Ruiz, I.; Asumendi, A.; Pérez-Yarza, G.; Gardeazabal, J.; Díaz-Ramón, J. L.; Boyano, M. D., H1 histamine receptor antagonists induce genotoxic and caspase-2-dependent apoptosis in human melanoma cells. Carcinogenesis 2006, 27, 1787-1796. 34. Jangi, S. M.; Ruiz-Larrea, M. B.; Nicolau-Galmés, F.; Andollo, N.; Arroyo-Berdugo, Y.; Ortega-Martínez, I.; Díaz-Pérez, J. L.; Boyano, M. D., Terfenadine-induced apoptosis in human melanoma cells is mediated through Ca2+ homeostasis modulation and tyrosine kinase activity, independently of H1 histamine receptors. Carcinogenesis 2008, 29, 500-509. 35. Francesca, N. G.; Aintzane, A.; Erika, A. T.; Gorka, P.Y.; Shawkat-Muhialdin, J.; Jesu´s, G.; Yoana, A. B.; Jesu´s, M. C.; Jose, L. D-R.; Aintzane, A. ; Marı´a, D. B., Terfenadine induces apoptosis and autophagy in melanoma cells through ROS-dependent and -independent mechanisms. Apoptosis 2011, 16, 1253-1267. 36. Elmore, S., Apoptosis: a review of programmed cell death. Toxicologic Pathology 2007, 35, 495-516. 37. Cotter, T. G., Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009, 9, 501-507. 38. Kerr, J.; Wyllie, A.; Currie, A., Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. British Journal of Cancer. 1972, 26, 239-257. 39. Adams, J. M., Ways of dying: multiple pathways to apoptosis. Genes & Development 2003, 17, 2481-2495. 40. MacFarlane, M., Cell death pathways – potential therapeutic targets. Xenobiotica 2009, 39, 616-624. 41. MacFarlane, M.; Williams, A. C., Apoptosis and disease: a life or death decision. EMBO Report 2004, 5, 674-678. 42. Riedl, S. J.; Shi, Y., Molecular mechanisms of caspase regulation during apoptosis. Nature Reviews Molecular Cell Biology 2004, 5, 897-907. 43. Ola, M. S.; Nawaz, M.; Ahsan, H., Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Molecular and Cellular Biochemistry 2011, 351, 41-58. 44. Youle, R. J.; Strasser, A., The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology 2008, 9, 47-59. 45. Borutaite, V., Mitochondria as decision-makers in cell death. Environmental and Molecular Mutagenesis 2010, 51, 406-416. 46. Salvesen, G. S.; Duckett, C. S., IAP proteins: blocking the road to death's door. Nature Reviews Molecular Cell Biology 2002, 3, 401-410. 47. G van Loo; X Saelens; M van Gurp; M MacFarlane; S J Martin; P Vandenabeele, The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death and Differentiation 2002, 9, 1031-1042. 48. MH Harris; CB Thompson, The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death and Differentiation 2000, 7, 1182-1191. 49. Martinou, J.-C.; Youle, Richard J., Mitochondria in Apoptosis: Bcl-2 Family Members and Mitochondrial Dynamics. Developmental Cell 2011, 21, 92-101. 50. Yip, K. W.; Reed, J. C., Bcl-2 family proteins and cancer. Oncogene 2008, 27, 6398-6406. 51. Brenner, D.; Mak, T. W., Mitochondrial cell death effectors. Current Opinion in Cell Biology 2009, 21, 871-877. 52. Rana, E.; Konstantinos, V. F.; Jerry, E. C., The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment. Genes & Cancer 2011, 5, 523-537. 53. Veis, D. J.; Sorenson, C. M.; Shutter, J. R.; Korsmeyer, S. J., Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993, 75, 229-240. 54. Kvansakul, M.; Yang, H.; Fairlie, W. D.; Czabotar, P. E.; Fischer, S. F.; Perugini, M. A.; Huang, D. C. S.; Colman, P. M., Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death & Differentiation 2008, 15, 1564-1571. 55. Westphal, D.; Dewson, G.; Czabotar, P. E.; Kluck, R. M., Molecular biology of Bax and Bak activation and action. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2011, 1813, 521-531. 56. Wei, M. C.; Zong, W.-X.; Cheng, E. H.-Y.; Lindsten, T.; Panoutsakopoulou, V.; Ross, A. J.; Roth, K. A.; MacGregor, G. R.; Thompson, C. B.; Korsmeyer, S. J., Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death. Science 2001, 292 , 727-730. 57. Wolter, K. G.; Hsu, Y.-T.; Smith, C. L.; Nechushtan, A.; Xi, X.-G.; Youle, R. J., Movement of Bax from the Cytosol to Mitochondria during Apoptosis. The Journal of Cell Biology 1997, 139, 1281-1292. 58. Simon, N.; Lin Chen, W.; Dewson, G.; Wei, A.; Naik, E.; I. Fletcher, J.; M. Adams, J.; David, C. S. H., Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes & Development 2005, 19, 1294-1305. 59. Mikhailov, V.; Mikhailova, M.; Degenhardt, K.; Venkatachalam, M. A.; White, E.; Saikumar, P., Association of Bax and Bak Homo-oligomers in Mitochondria. Journal of Biological Chemistry 2003, 278, 5367-5376. 60. Jiang, M.; Wang, C.-Y.; Huang, S.; Yang, T.; Dong, Z., Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway. American Journal of Physiology - Renal Physiology 2009, 296, F983-F993. 61. Bruno, A.; Sylvie, M.; Sandra, L.; Robert, E.; Jean-Claude, M., Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochemical Journal 2000, 345, 271-278. 62. Michael, W. C.; Tullia, L.; Vamsi, M. K.; Solly, W.; Atan, G.; Mona, A.; Craig, T. B.; Stanley, K. J., tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes & Development 2000, 14, 2060-2071. 63. Kim, H.; Tu, H.-C.; Ren, D.; Takeuchi, O.; Jeffers, J. R.; Zambetti, G. P.; Hsieh, J. J. D.; Cheng, E. H. Y., Stepwise Activation of BAX and BAK by tBID, BIM, and PUMA Initiates Mitochondrial Apoptosis. Molecular Cell 2009, 36, 487-499. 64. Puthalakath, H.; Strasser, A., Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death & Differentiation 2002, 9, 505-512. 65. Oda, E.; Ohki, R.; Murasawa, H.; Nemoto, J.; Shibue, T.; Yamashita, T.; Tokino, T.; Taniguchi, T.; Tanaka, N., Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis. Science 2000, 288, 1053-1058. 66. Nakano, K.; Vousden, K. H., PUMA, a Novel Proapoptotic Gene, Is Induced by p53. Molecular Cell 2001, 7, 683-694. 67. Zha, J.; Harada, H.; Yang, E.; Jockel, J.; Korsmeyer, S. J., Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL. Cell 1996, 87, 619-628. 68. Li, H.; Zhu, H.; Xu, C.-j.; Yuan, J., Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis. Cell 1998, 94, 491-501. 69. Kuwana, T.; Bouchier-Hayes, L.; Chipuk, J. E.; Bonzon, C.; Sullivan, B. A.; Green, D. R.; Newmeyer, D. D., BH3 Domains of BH3-Only Proteins Differentially Regulate Bax-Mediated Mitochondrial Membrane Permeabilization Both Directly and Indirectly. Molecular Cell 2005, 17, 525-535. 70. Chipuk, J. E.; Green, D. R., PUMA cooperates with direct activator proteins to promote mitochondrial outer membrane permeabilization and apoptosis. Cell Cycle 2009, 8, 2692-2696. 71. Ren, D.; Tu, H.-C.; Kim, H.; Wang, G. X.; Bean, G. R.; Takeuchi, O.; Jeffers, J. R.; Zambetti, G. P.; Hsieh, J. J.-D.; Cheng, E. H.-Y., BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program. Science 2010, 330, 1390-1393. 72. Leber, B.; Lin, J.; Andrews, D., Embedded together: The life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 2007, 12, 897-911. 73. Chipuk, J. E.; Moldoveanu, T.; Llambi, F.; Parsons, M. J.; Green, D. R., The BCL-2 Family Reunion. Molecular Cell 2010, 37, 299-310. 74. Umer, B.; Good, D.; Ann, J.; Duan, W.; Wei, M. Q., Clostridial Spores for Cancer Therapy: Targeting Solid Tumour Microenvironment. Journal of Toxicology 2012, 2012, 8. 75. Carew, J.; Huang, P., Mitochondrial defects in cancer. Molecular Cancer 2002, 1 , 9. 76. Modica-Napolitano, J. S.; Singh, K. K., Mitochondrial dysfunction in cancer. Mitochondrion 2004, 4, 755-762. 77. Gogvadze, V.; Orrenius, S.; Zhivotovsky, B., Mitochondria in cancer cells: what is so special about them? Trends in Cell Biology 2008, 18, 165-173. 78. Trachootham, D.; Zhou, Y.; Zhang, H.; Demizu, Y.; Chen, Z.; Pelicano, H.; Chiao, P. J.; Achanta, G.; Arlinghaus, R. B.; Liu, J.; Huang, P., Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell 2006, 10, 241-252. 79. Xiao, D.; Lew, K. L.; Zeng, Y.; Xiao, H.; Marynowski, S. W.; Dhir, R.; Singh, S. V., Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential. Carcinogenesis 2006, 27, 2223-2234. 80. Schulz, T. J.; Thierbach, R.; Voigt, A.; Drewes, G.; Mietzner, B.; Steinberg, P.; Pfeiffer, A. F. H.; Ristow, M., Induction of Oxidative Metabolism by Mitochondrial Frataxin Inhibits Cancer Growth. Journal of Biological Chemistry 2006, 281, 977-981. 81. Fantin, V. R.; St-Pierre, J.; Leder, P., Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9, 425-434. 82. Beckers, A.; Organe, S.; Timmermans, L.; Scheys, K.; Peeters, A.; Brusselmans, K.; Verhoeven, G.; Swinnen, J. V., Chemical Inhibition of Acetyl-CoA Carboxylase Induces Growth Arrest and Cytotoxicity Selectively in Cancer Cells. Cancer Research 2007, 67, 8180-8187. 83. Fulda, S.; Galluzzi, L.; Kroemer, G., Targeting mitochondria for cancer therapy. Nature Reviews Drug Discovery 2010, 9, 447-464. 84. Nika, N. D., BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death. Clinical Cancer Research 2007, 13, 7254-7263. 85. Kuwana, T.; Newmeyer, D. D., Bcl-2-family proteins and the role of mitochondria in apoptosis. Current Opinion in Cell Biology 2003, 15, 691-699. 86. Akgul, C., Mcl-1 is a potential therapeutic target in multiple types of cancer Cellular and Molecular Life Sciences 2009, 66, 1326-1336. 87. Michels, J.; O'Neill, J. W.; Dallman, C. L.; Mouzakiti, A.; Habens, F.; Brimmell, M.; Zhang, K. Y. J.; Craig, R. W.; Marcusson, E. G.; Johnson, P. W. M.; Packham, G., Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene 2004, 23, 4818-4827. 88. Podar, K.; Gouill, S. L.; Zhang, J.; Opferman, J. T.; Zorn, E.; Tai, Y. T.; Hideshima, T.; Amiot, M.; Chauhan, D.; Harousseau, J. L.; Anderson, K. C., A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene 2007, 27, 721-731. 89. Michels, J.; Johnson, P. W. M.; Packham, G., Mcl-1. The International Journal of Biochemistry & Cell Biology 2005, 37, 267-271. 90. Modjtahedi, N.; Giordanetto, F.; Madeo, F.; Kroemer, G., Apoptosis-inducing factor: vital and lethal. Trends in Cell Biology 2006, 16, 264-272. 91. Griffiths, G. J.; Dubrez, L.; Morgan, C. P.; Jones, N. A.; Whitehouse, J.; Corfe, B. M.; Dive, C.; Hickman, J. A., Cell Damage-induced Conformational Changes of the Pro-Apoptotic Protein Bak In Vivo Precede the Onset of Apoptosis. The Journal of Cell Biology 1999, 144, 903-914. 92. Panaretakis, T.; Pokrovskaja, K.; Shoshan, M. C.; Grandér, D., Activation of Bak, Bax, and BH3-only Proteins in the Apoptotic Response to Doxorubicin. Journal of Biological Chemistry 2002, 277, 44317-44326. 93. Mandic, A.; Viktorsson, K.; Molin, M.; Akusjärvi, G.; Eguchi, H.; Hayashi, S.-I.; Toi, M.; Hansson, J.; Linder, S.; Shoshan, M. C., Cisplatin Induces the Proapoptotic Conformation of Bak in a ΔMEKK1-Dependent Manner. Molecular and Cellular Biology 2001, 21, 3684-3691. 94. Meenakshi, U.; Rong, C.; Elena, G.; Sherri, S. K.; Timothy, C. C., Key role for Bak activation and Bak-Bax interaction in the apoptotic response to vinblastine. Molecular Cancer Therapeutics 2008, 7, 2224-2232. 95. Zhang, L.; Shimizu, S.; Sakamaki, K.; Yonehara, S.; Tsujimoto, Y., A Caspase-8-independent Signaling Pathway Activated by Fas Ligation Leads to Exposure of the Bak N Terminus. Journal of Biological Chemistry 2004, 279, 33865-33874. 96. Chandra, D.; Choy, G.; Daniel, P. T.; Tang, D. G., Bax-dependent Regulation of Bak by Voltage-dependent Anion Channel 2. Journal of Biological Chemistry 2005, 280, 19051-19061. 97. McCubrey, J. A.; Steelman, L. S.; Chappell, W. H.; Abrams, S. L.; Wong, E. W. T.; Chang, F.; Lehmann, B.; Terrian, D. M.; Milella, M.; Tafuri, A.; Stivala, F.; Libra, M.; Basecke, J.; Evangelisti, C.; Martelli, A. M.; Franklin, R. A., Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2007, 1773, 1263-1284. 98. Lei, K.; Nimnual, A.; Zong, W.-X.; Kennedy, N. J.; Flavell, R. A.; Thompson, C. B.; Bar-Sagi, D.; Davis, R. J., The Bax Subfamily of Bcl2-Related Proteins Is Essential for Apoptotic Signal Transduction by c-Jun NH2-Terminal Kinase. Molecular and Cellular Biology 2002, 22, 4929-4942. 99. Choi, S.-Y.; Kim, M.-J.; Kang, C.-M.; Bae, S.; Cho, C.-K.; Soh, J.-W.; Kim, J.-H.; Kang, S.; Chung, H. Y.; Lee, Y.-S.; Lee, S.-J., Activation of Bak and Bax through c-Abl-Protein Kinase Cδ-p38 MAPK Signaling in Response to Ionizing Radiation in Human Non-small Cell Lung Cancer Cells. Journal of Biological Chemistry 2006, 281, 7049-7059. 100. Ihrlund, L. S.; Hernlund, E.; Viktorsson, K.; Panaretakis, T.; Barna, G.; Sabapathy, K.; Linder, S.; Shoshan, M. C., Two distinct steps of Bak regulation during apoptotic stress signaling: Different roles of MEKK1 and JNK1. Experimental Cell Research 2006, 312, 1581-1589. 101. Wang, D.; Lippard, S. J., Cellular processing of platinum anticancer drugs. Nature Review Drug Discovery 2005, 4, 307-320. 102. Zhivotovsky, B.; Orrenius, S., Caspase-2 function in response to DNA damage. Biochemical and Biophysical Research Communications 2005, 331, 859-867. 103. Vakifahmetoglu, H.; Olsson, M.; Orrenius, S.; Zhivotovsky, B., Functional connection between p53 and caspase-2 is essential for apoptosis induced by DNA damage. Oncogene 2006, 25, 5683-5692. 104. Pietenpol, J. A.; Stewart, Z. A., Cell cycle checkpoint signaling : Cell cycle arrest versus apoptosis. Toxicology 2002, 181–182, 475-481. 105. Bartek, J.; Lukas, J., Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003, 3, 421-429. 106. Freeman, A.; Monteiro, A., Phosphatases in the cellular response to DNA damage. Cell Communication and Signaling 2010, 8, 27. 107. Treuner, K.; Knippers, R.; Fackelmayer, F. O.; Okuyama, A., Hyperphosphorylation of replication protein A middle subunit (RPA32) in apoptosis. Nucleic Acids Research 1999, 27, 1499-1504. 108. Treuner, K.; Findeisen, M.; Strausfeld, U.; Knippers, R., Phosphorylation of Replication Protein A Middle Subunit (RPA32) Leads to a Disassembly of the RPA Heterotrimer. Journal of Biological Chemistry 1999, 274, 15556-15561. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65510 | - |
dc.description.abstract | 惡性腫瘤為世界死因排名的第一位,其中,前列腺癌為全球男性罹患率第一高且死亡機率為第六位。近年來,國人前列腺癌的發生率與死亡率有逐漸增加的趨勢。雖然目前有許多前列腺癌的治療方法,像是手術治療、放射線治療、荷爾蒙阻斷療法及化學療法;但是,一旦荷爾蒙阻斷後疾病仍持續惡化則稱為荷爾蒙抗性前列腺癌,針對此種類型的前列腺癌其治療方法仍然有限。因此,發展有效治療荷爾蒙抗性前列腺癌的藥物為當前之急。
在本研究中,我們探討四種不同的H1組織胺受體拮抗劑在人類荷爾蒙不依賴性前列腺癌中的抗癌機制。首先,發現在四種H1組織胺受體拮抗劑中 (包含Terfenadine、Loratadine、Fexofenadine及Diphenhydramine),其中以Terfenadine抑制癌細胞生長的效果最佳,而且在PC-3和DU-145細胞都有抑制的作用,因此,選擇Terfenadine作後續更深入的抗癌機制探討。接著,由流式細胞儀的分析結果發現,細胞週期之subG1期的細胞數會增加,代表Terfenadine會造成細胞凋亡的現象。利用西方墨點法偵測與細胞凋亡相關的蛋白表現量,結果發現Terfenadine的作用下會迅速地造成促凋亡蛋白Bak表現量增加,及抗凋亡蛋白Mcl-1產生cleavage (28kDa),而且此現象與時間呈正相關性;接著會造成後續PARP-1蛋白的斷裂及Caspase-9、-7和-3的活化。此外,藉由可以辨認Bak活化時之特殊構型的抗體進行偵測,結果發現具有功能性的Bak增加後會使得粒線體膜電位下降,進一步造成凋亡因子cytochrome C和apoptosis inducing factor (AIF) 釋出到細胞質中。另外,同時利用RT-PCR與Real-time PCR的技術偵測,發現在轉錄的調控上使Bak mRNA增加,進而蛋白表現量上升。當藥物處理到晚期的時間點,亦會影響到DNA損傷相關蛋白的表現量,導致DNA損傷的發生。總體而言,Terfenadine會先造成有功能性的Bak蛋白表現量增加及Mcl-1蛋白的降解,進一步影響粒線體的結構,使得粒線體膜電位下降後,造成caspases的活化及DNA損傷,最終導致細胞死亡。 | zh_TW |
dc.description.abstract | Cancer is the world's leading cause of death. Among these cancers, prostate cancer is the most frequently diagnosed cancer and the sixth leading cause of cancer death in men. In Taiwan, the occurrence and mortality rate of prostate cancer has increased over the past few years. There are several therapies for prostate cancer, such as surgery, radiation therapy, hormone deprivation therapy, and chemotherapy. However, the therapies for treating patients with hormone-refractory prostate cancers (HRPCs), which are become resistant to hormone therapy, are limite. Therefore, novel therapeutic agents for treating HRPC are urgently demanded.
In this study, we have demonstrated the anticancer mechanism of H1-receptor antagonists in human HRPCs. First, the effect of four H1-receptor antagonists, including Terfenadine, Loratadine, Fexofenadine, and Diphenhydramine on cell proliferation was examined. The data showed that Terfenadine was the most potent, displaying an antiproliferative activity in both human HRPC cell lines PC-3 and DU-145. We choosed Terfenadine to do further study in detail. The flow cytometric analysis showed that terfenadine induced an increase of subG1-phase population of the cell cycle. By using Western blot analysis, we found that Terfenadine rapidly induced Bak up-regulation and Mcl-1 degredation in time-dependent manner, leading PARP-1 cleavage and proteolytic activation of caspase -9, -7, and -3. Moreover, by using specific antibody to recognize activated Bak, it showed that the increase of functional Bak was correlated to the loss of mitochondria membrane potential, subsequently leading to the release of cytochrome C and apoptosis-inducing factor (AIF) to cytosol. We also found that Bak up-regulation in protein levels was due to increase of mRNA levels. The DNA damage was also induced by Terfenadine and was associated with the proteolytic activation of capsase cascades, which in turn caused further up-regulation of DNA-damage related proteins. In summary, the data suggest that terfenadine induces up-regulation of functional Bak and Mcl-1 degradation, leading to the loss of mitochondrial membrane potential and the activation of caspase cascades that ultimately induce DNA damage and apoptotic cell death. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T23:47:26Z (GMT). No. of bitstreams: 1 ntu-101-R99423012-1.pdf: 2790567 bytes, checksum: 243f252ed9bbd496530eb0d52c5e0ec8 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 口試委員會審定書 ………………………………………………I
誌謝 ………………………………………………………………II 目錄 ………………………………………………………………III 圖目錄 ……………………………………………………………V 縮寫表 ……………………………………………………………VII 中文摘要 ……………………………………………………IX 英文摘要 ……………………………………………………X 一、研究動機與目的 ……………………………………………………1 二、背景 …………………………………………………… 2 三、實驗材料 …………………………………………………… 17 四、實驗方法 ……………………………………………………19 1.細胞培養 …………………………………………………… 19 2.細胞計數 ……………………………………………………19 3.細胞存活率測定 (SRB assay) ……………………………19 4.細胞群落形成的測定 (Colony formation assay)………20 5.流式細胞儀 (FACScan flow cytometry) 5.1測定細胞週期與細胞凋亡 …………………………… 21 5.2測定粒線體膜電位 …………………………………… 21 5.3測定Bak蛋白質活化程度 …………………………… 22 6.西方墨點法 (Western blot) …………………………… 23 7.萃取分離粒線體蛋白 …………………………………… 26 8.反轉錄酶-聚合酶鏈合反應 (RT-PCR) …………………27 9.即時定量-聚合酶鏈合反應 (Real Time-PCR) …………… 29 10.細胞轉染 (transfection) ………………………… 29 11.Comet assay …………………………………… 30 12.資料分析 …………………………………… 30 五、實驗結果 ……………………………………31 六、實驗討論 ……………………………………37 七、總結與展望 ……………………………………44 八、圖表 …………………………………… 45 九、參考文獻 …………………………………… 76 | |
dc.language.iso | zh-TW | |
dc.title | 第一型組織胺受體拮抗劑在人類雄性激素不依賴型前列腺癌細胞的抗癌作用機轉研究 | zh_TW |
dc.title | Study of Anticancer Mechanism of H1 Receptor Antagonists in Human Androgen-Independent Prostate Cancer Cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 顧記華(Jih-Hwa Guh) | |
dc.contributor.oralexamcommittee | 楊家榮,黃聰龍,蕭哲志 | |
dc.subject.keyword | 前列腺癌,組織胺受體拮抗劑,內生性細胞凋亡, | zh_TW |
dc.subject.keyword | prostate cancer,terfenadine,bak, | en |
dc.relation.page | 85 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-07-24 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 2.73 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。